logo

Bellus Health Inc (BLU)



Trade BLU now with
  Date
  Headline
9/13/2021 7:49:17 AM BELLUS Health Announces Positive Interim Analysis From Phase 2b SOOTHE Trial Of BLU-5937 In Refractory Chronic Cough
8/23/2021 7:08:52 AM BELLUS Health To Report Additional RELIEF Data In Oral Presentation At ERS International Congress 2021
3/24/2021 7:13:32 AM BELLUS Health Appoints William Mezzanotte To Board
3/17/2021 9:07:17 PM Forum Merger IV Corp. Prices IPO Of 30 Mln Units At $10.00/unit
12/14/2020 7:06:54 AM BELLUS Health Says First Patient Dosed In Phase 2 BLUEPRINT Trial Of BLU-5937
12/8/2020 7:11:53 AM BELLUS Health Announces First Patient Dosed In Phase 2b SOOTHE Trial Of BLU-5937 For Refractory Chronic Cough
12/7/2020 7:11:32 AM BELLUS Health Appoints Ramzi Benamar As CFO
11/12/2020 7:41:21 AM Amended: BELLUS Health Q3 Net Loss $5.7 Mln Vs. Net Loss $6.5 Mln Last Year
10/22/2020 9:23:27 AM BELLUS Health Closes $40 Mln Public Offering Of Common Shares
10/19/2020 11:33:42 PM BELLUS Health Announces Pricing Of US$35 Mln Public Offering In Canada And U.S.
9/8/2020 7:09:35 AM BELLUS Health Announces Design For Phase 2b Trial With BLU-5937 In RefractoryChronic Cough
8/13/2020 7:11:45 AM BELLUS Health Q2 Net Loss $8.42 Mln Or $0.14/Shr Vs Loss $5.91 Mln Or $0.13/Shr Last Year
7/6/2020 7:06:19 AM BELLUS Health Says Phase 2 RELIEF Trial Of BLU-5937 Did Not Achieve Statistical Significance For Primary Endpoint
3/23/2020 7:35:05 AM BELLUS Health Agrees To Acquire Remaining BLU-5937 And Related P2X3 Antagonists Intellectual Property Assets
3/19/2020 7:04:10 AM BELLUS Health Announces Completion Of Enrollment In Phase 2 RELIEF Trial Of BLU-5937 For Refractory Chronic Cough